doi: 10.3233/JAD-2002-4605 73
[DOI] [PubMed] [Google Scholar] Ahmed MA, OCallaghan C, Chang ED, Jiang H, Vassilopoulos A
As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant safety risks, and the agency has scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 2026 covering proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy
Every visit is with a doctor, not a mid-level provider, and the talk starts with your full health storysleep, stress, micronutrientsbefore testosterone even comes up
For example, prohibitin 1 (PHB1) is a ubiquitous protein expressed in multiple subcellular regions but primarily in the inner mitochondrial membrane
Some patients start with a short series of NAD+ treatments for deeper support, then move to maintenance sessions spaced weeks or months apart